摘要
Background: Hepatocellular carcinoma (HCC) is one of the most common and deadly tumors worldwide. Immunotherapy has emerged as a promising strategy for HCC treatment, and understanding the immune microenvironment of HCC provides a theoretical basis for identifying new immune targets. However, the roles of immune components and their regulatory mechanisms in HCC require further clarified. @@@ Methods: By analyzing HCC expression profiles from The Cancer Genome Atlas (TCGA) database, we depicted the proportion profile of immune cells for each sample using the software CIBERSORTx. Using R packages, we also characterized the distribution of differentially expressed genes (DEGs) in immune cells, calculated the correlation coefficient between immune cells and common DEGs, and analyzed their biology function by Gene-Ontology analysis. @@@ Results: We found that seven immune cell types were related to the overall survival of HCC patients, and identified 3,692 differentially expressed immune-related genes, predominantly functioning in nucleic acid processing and metabolism. Moreover, 14 DEGs were identified as common candidates related to immune cells and overall survival. @@@ Conclusions: Our study not only presents an overview of the immune features of the microenvironment of HCC, but also provides potential targets related to immune components.
学科与关键词
- Identification and analysis of immune-related subtypes of hepatocellular carcinomaWang, Qimeng; Huang, Jin; Zhang, Huihua; Liu, Huan*; Yu, Min*Experimental Biology and Medicine, 2021, 246(6): 667-677.被引 2
- Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma.Li, Yue; He, Xiaoqin; Zhang, Xiaoyu; Xu, Yangtao; Wu, Yaogui*; Xu, Ximing*Life Sciences, 2021, 265: 118799.
- A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironmentZeng, Chunting; Zhang, Linmeng; Luo, Chanhua; Yang, Chen; Huang, Xiaowen; Fan, Linfeng; Li, Jiarong; Chen, Fengsheng*; Luo, Zelong*BMC CANCER, 2022, 22(1): 613.
